ImmunoModulary Solutions - ! SECOND PLACE !
Product/Service: Drug Discovery and Development
Contact: Tsafrir Vanounou
tvanounou@mba2004.hbs.edu
(617) 731-8469

Multiple sclerosis (MS) is a chronic debilitating disease of the central nervous system which afflicts young adults in the prime of their lives. Approximately 400,000 people in the United States and about 3 million people worldwide have MS. These patients have few effective therapeutic options available. All current MS disease-modifying therapies are only marginally effective in delaying disease progression, involve painful injections and are plagued with significant side effects. ImmunoModulary Solutions (IMS) addresses this underserved $2.5 billion MS therapeutic market by introducing the first oral therapeutic for MS. IMS’s patent pending formulation, Immureg, will target the MS market with a highly effective and safe oral therapeutic. Immureg has undergone over 4 years of pre-clinical validation and has been conclusively demonstrated to dramatically reduce or eliminate the neurological impairment seen in all established rodent models of MS.
[ back to top ]

 

Mujisan Pharmaceuticals - ! RUNNER UP !
Product/Service: Drug Delivery
Contact: David Wang
davidwang@stanford.edu
(650) 799-2376

Mujisan Pharmaceuticals is a start-up drug delivery company based on our proprietary drug polymer technology, PolyRx. It represents a novel sustained-release (SR) formulation strategy that forms polymers using individual drug molecules as the building blocks. The key advantages of this technology are two-fold: (1) The SR mechanism is tamper-proof as the active drug is released only physiologically and, unlike competing platforms, cannot be mechanically compromised; (2) more drug can be loaded in each pill, allowing for SR for 24 hours and thus improved analgesic efficacy.
[ back to top ]

AMC Scientific LLP
Product/Service: Medical Instrumentation/Optical Imaging
Contact: Andrea Pierce
andiepi@msn.com
(603) 860-4899

AMP Scientific LLC, a NH woman-owned small business, is to develop a low-cost, easy to use optical imaging system for a clinical pathology laboratory. Working in collaboration with a local university hospital, we have identified a niche opportunity to fill in this lucrative, $ 6.1 billion imaging equipment market.
[ back to top ]

---

Ligeia
Product/Service: Drug Discovery and Development
Contact: Daniel Janse
Daniel_Janse@student.hms.harvard.edu

I-Shield Technologies
Product/Service: Technology Platform
Contact: Michael Berg
mcberg@mit.edu
(617) 253-6921

I-Shield Technologies solves important biomedical problems by applying proprietary technologies developed in the laboratories of MIT. I-Shield will use a licensing business model to drive over $35MM in pretax cashflow by our third year. We will do so by exploiting our proprietary technology platform to address fundamental medical issues in artificial knees and hips, breast implants, post-operative adhesions, coronary stents, and other areas in a sequential manner.
[ back to top ]

Cure Works
Product/Service: Vaccine Formulation Venture
Contact: Evan Schwartz
eschwart@fas.harvard.edu
(617) 869-9089

CureWorks is a not-for-profit vaccine formulation venture dedicated to developing solutions for today’s urgent problems in global health and infectious disease. The company’s first project will be creating a single administration vaccine for Malaria, one of the world’s most notorious killers. CureWorks’ vaccine strategy employs a novel sustained-release delivery technology combined with leading malarial antigen candidates.
[ back to top ]

---

Agrivida
Product/Service: Ag-Biotech
Contact: Kyle Jensen
kljensen@agrivida.com
(617) 253-6521

Agrivida turns plants and agricultural wastes into renewable fuels. We use a novel breed of corn to manufacture ethanol, an environmentally–friendly and domestically–produced fuel. Through its natural growth process, this corn makes proteins that carry out major steps in ethanol production, resulting in significant capital and operating cost savings versus ethanol production using ordinary corn.
[ back to top ]

---

Extend Fertility Inc
Product/Service: Female Fertility
Contact: Christina Carlisle
cjones@extendfertility.com
(800) 841-7197 ext. 85

Extend Fertility is dedicated to enriching the lives of women through revolutionary science and service that effectively slows down the biological clock. Using an exclusive FDA-approved product, Extend freezes clients’ healthy, “young” eggs and preserves them for use in the future. By cryo-preserving their eggs in a “suspended state”, Extend clients can expect a pregnancy success rate later in life similar to their natural peak fertility rate of 25%.
[ back to top ]

---

Hestion Corp
Product/Service: Antimicrobial Technology Platform
Contact: Richard G. Wehby
rgw@mit.edu
(617) 327-8218

Hestion is a seed-stage company with a patent-pending technology that imparts permanent antimicrobial activity to any material. The technology kills microbes on contact without creating antimicrobial resistance. Hestion's founding team includes the MIT and Northeastern University inventors of the technology, and represents a credible background of scientific and business expertise.
[ back to top ]

---

Biological Energy Corporation
Product/Service: Hydrogen Production
Contact: Richard Resnick
rjr@sloan.mit.edu
(617) 429-3549

Biological Energy Corporation (BEC) is developing breakthrough patent-pending approaches to produce hydrogen photobiologically through genetic and environmental modifications of microorganisms. Industries currently requiring hydrogen include petroleum refining, metallurgy, semi-conductors, glass, fertilizer, pharmaceuticals, and foods. BEC intends to use these existing and expanding markets to establish a position to enter and establish a potentially dominant position in the developing hydrogen economy over the next ten years.
[ back to top ]

---

SynerZ
Product/Service: Drug Discovery and Development
Contact: Lixin Zhang
lzhang03@comcast.net
(617) 285-6314

SynerZ is a seed-stage drug discovery company that targets multiple disease pathways simultaneously. This synergistic premise offers a way of resurrecting drugs whose patents are expiring or rescuing drug candidates abandoned because of inadequate safety profiles. Co-founded by Nobel Prize Laureate, National Academy Members and successful business executives, SynerZ uses a proprietary concept and a technology platform to rapidly identify and discover novel synergistic drugs systematically.
[ back to top ]

---

BioForge
Product/Service: Drug Discovery for HIV/AIDS
Contact: Bryan Foose
bfoose@mail.com
(613) 557-5228

BioForge will be a pharmaceutical product development company that intends to design, patent, and market structure based drug candidates for HIV/AIDS and other viral markets. Two assays have already been designed with the participation of leading researchers at Harvard University. These assays will be available for immediate screening of chemical libraries. Additionally, BioForge intends to develop and patent processes for the cheap and easy purification of Peptide drugs expressed in bacterial cell systems.
[ back to top ]

---

Diamont Diagnostics
Product/Service: Technology Platform
Contact: Anand Bala Subramaniam
balasubr@fas.harvard.edu

The core DIAMONT idea is a novel combination of Harvard microfluidics technology and a miniaturized Surface Plasmon Resonance (SPR) sensor. Our product holds promise for use by a variety of individuals, including medical professionals and military personnel in a vast array of diagnostic settings from laboratories to harsh environments. DIAMONT will develop its first diagnostic product for SARS in close interaction with military diagnostic labs.
[ back to top ]

---

Tranvera Technologies
Product/Service: Drug Delivery
Contact: Brandon Harris Molina
bmolina@fas.harvard.edu

Transvera is a material transport company seeking to apply its expertise in molecular transport phenomena to real world problems. Transvera's first product line will take advantage of an existing gap in current transdermal drug delivery solutions. By approaching the barriers to transdermal drug delivery from the standpoint of material transport, Transvera has developed a proprietary technology that will increase the diffusion rate of large molecular weight drugs to therapeutic rates.
[ back to top ]

---

Adaptive Significant IT
Product/Service: Technology Platform
Contact: Steve Kemperle
SteveK@AdaptivesignificantIT.com
Info@adaptivesignificantit.com

Adaptive Significant Information Technology's brilliant “vision/mission” is to research and develop futuristic “Adaptive Quantum Information Technology”/Genomics products, services & technology. Founded in the year 2000 to altruistically help rethink, enhance & engage concepts in Quantum Information Technology, Optical Quantum Information Technology [OQIT], & Genomics R&D. As per the general model of Naturalizin Computational Environments & engaging the maximisation of the business of “In-Silico” Adaptive Quantum IT, [OQIT], & Genomics R&D.
[ back to top ]